Читать книгу Blood and Marrow Transplantation Long Term Management - Группа авторов - Страница 117

With an increasing knowledge on the incidence and risk‐factors of late effects in the context of specific diseases, steps should be taken to initiate survivorship planning right from diagnosis and develop a treatment plan that will help minimize late adverse effects in AHSCT survivors. AHSCT survivors have a lower adherence to age‐ and sex‐specific preventative care guidelines compared to allogeneic‐transplant survivors [81]. Since these patients are cared for by a diverse group of physicians including transplant and cellular therapy physicians, non‐transplant hematologist/oncologists, primary care physicians, and subspecialists, communication between care teams and development of patient‐centric models will enable better monitoring and management of late effects in this growing population.